全球止血剂市场规模（按类型、产品、应用、最终用户、区域范围和预测）

止血剂市场规模及预测

2024 年止血剂市场规模价值 43 亿美元，预计到 2032 年将达到 64.9 亿美元，2026 年至 2032 年的复合年增长率为 5.30%。

止血钳是用于在手术和紧急情况下快速有效地控制出血的材料。其作用机转为浓缩凝血因子、附着于出血组织或将促进要素输送至出血部位。止血钳可以是机械式的、主动式的或被动式的。

用于治疗缺乏凝血因子而引起的无法控制的大量出血、凝血障碍、外伤出血、脑出血、产后出血、大手术期间或之后的出血。

全球止血剂市场动态

影响止血剂市场的关键市场动态是：

关键市场驱动因素

外科手术数量的增加：全球外科手术数量的增加是止血剂市场的主要驱动力。根据世界卫生组织 (WHO) 的数据，全球外科手术数量正在持续增加。 《柳叶刀》杂誌发表的一项研究显示，2012 年全球共实施了 3.13 亿例外科手术，预计到 2030 年将增加至 4.584 亿例。外科手术数量的增加推动了对止血剂的需求，因为许多外科手术都需要良好的止血性能。

出血性疾病盛行率上升：出血性疾病盛行率上升推动了对止血剂的需求。根据世界血友病联盟 (WFH) 的数据，全球每 10,000 人中约有 1 人患有血友病。根据 WFH 2019 年年度全球调查，全球有 324,648 人患有出血性疾病，与前一年同期比较增加了 6%。出血性疾病患者群体的不断扩大需要在各种临床环境中使用止血剂。

创伤和急救病例增加：创伤病例的增多，尤其是机动车事故造成的创伤，正在推动止血剂市场的发展。根据世界卫生组织（WHO）2018年《全球道路安全状况报告》，每年约有135万人死于道路交通事故，另有2,000万至5,000万人遭受非致命性伤害。许多此类伤害需要紧急止血，这增加了急诊医疗和创伤护理中对止血剂的需求。

主要挑战

止血剂价格高昂：止血剂价格昂贵，这也是一个主要障碍，尤其是在医疗资金匮乏的开发中国家。许多最新的止血剂价格昂贵，因此无力负担的医院和诊所无法取得。这一经济障碍阻碍了在危急情况下采用更优质的药物，从而影响了患者的治疗效果和整体市场的成长。

副作用风险：某些止血药物的潜在副作用也限制了市场的成长。医疗保健专业人员由于担心过敏反应和组织损伤等潜在副作用而不愿使用这些产品。这些担忧有利于现有的止血程序，并限制了新型止血材料的市场接受度和使用。

主要趋势：

微创手术的兴起：微创手术的兴起对止血剂市场产生了重大影响。随着外科技术的进步，能够减少组织压力并缩短恢復时间的手术越来越受到青睐。在这种情况下，止血剂至关重要，因为它们能够控制出血，同时保护周围组织。这项发展推动了对专为微创手术设计的新型止血剂的需求。

技术进步：止血剂的技术发展正在影响市场格局。製造商正在加大研发投入，以开发更有效、更安全的产品。具有多种作用机制的复合止血剂越来越受欢迎。这些发展不仅改善了患者的治疗效果，也扩大了止血剂在各外科领域的应用。

慢性病的流行：慢性病的发生率不断上升，加上人口老化，推动了对止血剂的需求。慢性病需要外科手术治疗，因此出血控制至关重要的外科手术发生率更高。随着全球人口老化，预计外科手术数量将会增加，从而推动止血剂市场的发展。这一趋势凸显了医疗保健环境中建立完善的出血控制系统的重要性。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

第四章 止血剂市场（按类型）

• 凝血酶类止血剂
• 明胶基止血剂
• 胶原蛋白基止血剂
• 氧化再生纤维素止血材料
• 组合止血钳
• 纤维蛋白胶
• 其他的

第五章 止血剂市场（按产品）

• 主动型
• 被动的
• 组合
• 其他的

第六章 止血剂市场（依应用）

• 创伤外科
• 心血管外科
• 一般外科
• 整形外科
• 整形外科
• 神经外科

第七章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第八章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第九章 竞争态势

• 主要企业
• 市场占有率分析

第十章 公司简介

• Baxter International Inc.
• Becton, Dickinson and Company（BD）
• Pfizer Inc.
• Ethicon Inc.
• B. Braun SE
• Teleflex Incorporated
• CryoLife, Inc.
• Integra LifeSciences
• Advanced Medical Solutions Group plc
• GELITA AG

第十一章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十二章 附录

• 简称列表
• 来源和参考文献

Hemostatic Agents Market Size And Forecast

Hemostatic Agents Market size was valued at USD 4.3 Billion in 2024 and is projected to reach USD 6.49 Billion by 2032, growing at a CAGR of 5.30% from 2026 to 2032.

Hemostatic agents are materials used to control bleeding quickly and effectively during surgeries or in emergency situations. They function by concentrating coagulation factors, attaching to tissues where hemorrhage has occurred, or supplying procoagulant factors to the bleeding site. Hemostatic agents are characterized as mechanical, active, or passive.

They are used to treat uncontrollable large bleeding in the absence of clotting factors, coagulation abnormalities, hemorrhage caused by trauma, cerebral hemorrhage, postpartum hemorrhage, and bleeding during or after major surgeries.

Global Hemostatic Agents Market Dynamics

The key market dynamics that are shaping the hemostatic agents market include:

Key Market Drivers

Increasing number of Surgical Procedures: The growing number of surgical operations worldwide is a major driver of the hemostatic agents market. According to the World Health Organization (WHO), the number of procedures conducted worldwide has constantly increased. According to a study published in The Lancet, 313 million surgical procedures were performed worldwide in 2012, with the figure expected to rise to 458.4 million in 2030. The increase in surgical operations, many of which require good hemostasis, is pushing up demand for hemostatic agents.

Rising Prevalence of Bleeding Disorders: The growing prevalence of bleeding diseases is driving up the demand for hemostatic agents. According to the World Federation of Hemophilia (WFH), hemophilia affects approximately one out of every 10,000 persons worldwide. In their 2019 Annual Global Survey, the WFH found 324,648 people worldwide living with bleeding disorders, a 6% rise over the previous year. The expanding patient population with bleeding disorders necessitates the use of hemostatic agents in a variety of clinical settings.

Increasing Traumatic Injuries and Emergency Cases: The increased prevalence of traumatic injuries, notably from automobile accidents, is propelling the hemostatic agents market. According to the World Health Organization's Global Status Report on Road Safety 2018, roughly 1.35 million people die each year as a result of road traffic accidents, with another 20-50 million suffering non-fatal injuries. Many of these injuries necessitate urgent hemostasis, which increases the need for hemostatic agents in emergency and trauma care settings.

Key Challenges:

High Cost of Hemostatic Agents: Hemostatic agents are expensive, which is another major barrier, especially in developing nations where funds for healthcare are few. Many modern hemostatic products are expensive, rendering them inaccessible to hospitals and clinics that cannot pay the costs. This financial barrier impedes the adoption of good medicines in critical situations, affecting patient outcomes and overall market growth.

Risk of Adverse Reactions: The potential for adverse reactions to certain hemostatic medicines also limits market growth. Healthcare experts are hesitant to utilize these products because they are concerned about potential adverse effects such as allergic responses and tissue damage. This concern leads to a preference for existing hemostasis procedures, restricting the market's acceptance and use of new hemostatic agents.

Key Trends:

Increasing Adoption of Minimally Invasive Surgeries: The growing popularity of minimally invasive operations is having a significant impact on the hemostatic agents market. As surgical techniques advance, there is an increasing preference for operations that reduce tissue stress and recuperation time. Hemostatic medicines are essential in these situations because they help control bleeding while protecting surrounding tissues. This development is generating demand for novel hemostatic agents designed specifically for minimally invasive treatments.

Technological Advancements: Technological developments in hemostatic agents are influencing the market landscape. Manufacturers are spending in R&D to develop more effective and safe products, such as enhanced formulations and delivery technologies. Combination hemostats, which have numerous mechanisms of action, are gaining traction. These developments not only improve patient outcomes but also broaden the applications of hemostatic agents across various surgical specialties.

Growing Prevalence of Chronic Diseases: The increasing frequency of chronic diseases, combined with an aging population, is driving up demand for hemostatic agents. Chronic illnesses necessitate surgical procedures, resulting in a higher incidence of surgeries where bleeding management is essential. As the world's population ages, the number of surgical procedures is predicted to increase, boosting the market for hemostatic agents. This trend underscores the importance of appropriate bleeding management systems in healthcare settings.

Global Hemostatic Agents Market Regional Analysis

Here is a more detailed regional analysis of the hemostatic agents market:

North America:

According to Verified Market Research, North America is estimated to dominate the hemostatic agents market over the forecast period. North America has a high prevalence of cardiovascular disease, which necessitates a large number of cardiac procedures that require hemostatic agents. According to the American Heart Association's 2021 Heart Disease and Stroke Statistics update, about half of all American adults suffer from cardiovascular disease. According to the report, heart disease kills over 659,000 people in the United States each year, accounting for one out of every four deaths. Also, the Society of Thoracic Surgeons states that roughly 500,000 coronary artery bypass graft surgeries are conducted each year in the United States. This large volume of cardiac surgeries increases the demand for sophisticated hemostatic agents in the region.

Furthermore, North America has a high rate of traumatic injuries, mainly from car accidents and violence, necessitating the usage of hemostatic agents in emergency situations. According to the National Center for Health Statistics, unintentional injuries are the third greatest cause of death in the United States, with around 173,040 deaths in 2019. Also, the National Trauma Institute reports that trauma accounts for 41 million emergency department visits and 2.3 million hospital admissions across the country each year. This high volume of trauma patients greatly increases the demand for hemostatic agents in North America.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. The Asia-Pacific region has a high rate of traffic accidents, which result in traumatic injuries requiring hemostatic agents. According to the World Health Organization's Global Status Report on Road Safety 2018, Southeast Asia and the Western Pacific regions account for 62% of all road traffic deaths. In China alone, the Ministry of Public Security reported 203,049 road traffic accidents in 2019, with 62,763 fatalities and 226,751 injuries. The increased occurrence of traumatic injuries is increasing the demand for hemostatic agents in emergency and trauma care settings throughout Asia-Pacific.

Furthermore, the Asia-Pacific region is experiencing an increase in cardiovascular disorders, which necessitate surgical procedures and the usage of hemostatic agents. According to the Asian Pacific Society of Cardiology, cardiovascular disease (CVD) causes 35% of all fatalities in the Asia Pacific region. According to the World Heart Federation, by 2030, 4.5 million people will die from cardiovascular disease in Southeast Asia alone, up from 3.6 million in 2014. The rising prevalence of cardiovascular disorders is driving up demand for hemostatic agents in heart surgery and associated treatments.

Europe:

Europe region is estimated to exhibit substantial growth during the forecast period. Europe's significant investment in healthcare infrastructure and research is fueling innovation and acceptance of improved hemostatic agents. The European Commission states that healthcare spending in the EU reached 9.9% of GDP in 2018, with an average annual increase rate of 3.0% between 2013 and 2018. Medtech Europe reports that the European medical technology market was valued at €120 billion in 2018. This strong healthcare spending and emphasis on medical technology advancement are boosting the hemostatic agents market in Europe, as hospitals and healthcare providers invest in cutting-edge technologies to improve patient outcomes.

Furthermore, Europe has a high incidence of cardiovascular illnesses, which necessitate surgical treatments and the use of hemostatic agents. The European Heart Network claims that cardiovascular disease kills 3.9 million people in Europe each year, accounting for 45% of all deaths. According to the European Society of Cardiology, more than 11 million new instances of cardiovascular disease were diagnosed in Europe year 2015. The treatment of these disorders, particularly during surgical procedures, is driving up demand for hemostatic agents in the region.

Global Hemostatic Agents Market: Segmentation Analysis

The Hemostatic Agents Market is segmented based on Type, Product, Application, End-User, and Geography.

Hemostatic Agents Market, By Type

• Thrombin-based Hemostats
• Gelatin-based Hemostats
• Collagen-based Hemostats
• Oxidized Regenerated Cellulose-based Hemostats
• Combination Hemostats
• Fibrin Sealants
• Others

Based on Type, the market is segmented into Thrombin-based, Gelatin-based, Collagen-based, Oxidized Regenerated Cellulose-based, Combination, Fibrin Sealants, and Others. The oxidized regenerated cellulose-based hemostats segment is estimated to dominate the hemostatic agents market during the forecast period. These hemostatic agents have emerged as market leaders, demonstrating their efficacy in a wide range of surgical procedures, including general surgery, cardiovascular surgery, orthopedics, and other specialties. This versatility has made them an appealing option for surgeons who face a variety of clinical settings, contributing to their dominant market position.

Hemostatic Agents Market, By Product

• Active
• Passive
• Combination
• Others

Based on Product, the market is segmented into Active, Passive, Combination, and Others. The passive segment is estimated to dominate the hemostatic agents market due to the wide range of product options and the growing popularity of technologically improved passive hemostatic solutions. These medicines are preferred for their efficacy in limiting bleeding during various surgical operations, resulting in increased acceptability among healthcare professionals. Also, the ongoing development of innovative passive hemostatic technologies by prominent manufacturers contributes to this segment's market leadership.

Hemostatic Agents Market, By Application

• Trauma
• Cardiovascular Surgery
• General Surgery
• Plastic Surgery
• Orthopedic Surgery
• Neurosurgery
• Others

Based on Application, the market is divided into Trauma, Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, Neurosurgery, and Others. The general surgery segment is estimated to dominate the market over the forecast period. This dominance is driven by the growing number of surgical procedures performed worldwide, as general surgery comprises a wide range of operations that necessitate good bleeding control. The increased frequency of chronic diseases, as well as the demand for less invasive treatments, strengthen this segment, making it a vital area for hemostatic agent applications and contributing to its long-term market growth.

Hemostatic Agents Market, By End-User

• Hospitals
• Surgery Centers
• Nursing Homes
• Others

Based on End-User, the market is divided into Hospitals, Surgery Centers, Nursing Homes, and Others. The hospital segment is estimated to dominate the market over the forecast period due to the growing number of surgical procedures and the rising prevalence of chronic conditions that demand surgical interventions. Hospitals are prepared to manage difficult patients and provide comprehensive care, hence they are the principal environment for the administration of hemostatic drugs. As healthcare systems improve and expand, the need for good bleeding control in hospitals is projected to increase significantly.

Hemostatic Agents Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Hemostatic Agents Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to dominate during the forecasted period. The region benefits from modern healthcare infrastructure, substantial healthcare spending, and a large number of surgical procedures per year. Furthermore, the existence of key market competitors and the ongoing launch of innovative hemostatic products support market growth. The growing need for technologically advanced surgical solutions reinforces North America's leadership position in this market.

Key Players

• The "Hemostatic Agents Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Baxter International, Inc., Becton, Dickinson and Company (BD), Pfizer, Inc., Ethicon, Inc., B. Braun SE, Teleflex Incorporated, CryoLife, Inc., Integra LifeSciences, Advanced Medical Solutions Group plc, and GELITA AG.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Hemostatic Agents Market Recent Developments
• In November 2023, Johnson & Johnson's MedTech division, Ethicon, launched Ethizia, a hemostatic sealing patch with European approval. This marks a substantial boost to the company's medical services in Europe.
• In August 2023, Vizient Inc. issued HemoSonics an Innovative Technology Contract for their Quantra hemostasis system.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Hemostatic Agents Market, By Type

• Thrombin-based Hemostats
• Gelatin-based Hemostats
• Collagen-based Hemostats
• Oxidized Regenerated Cellulose-based Hemostats
• Combination Hemostats
• Fibrin Sealants
• Others

5. Hemostatic Agents Market, By Product

• Active
• Passive
• Combination
• Others

6. Hemostatic Agents Market, By Application

• Trauma surgery
• Cardiovascular surgery
• General surgery
• Plastic surgery
• Orthopedic surgery
• Neurosurgery

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Baxter International Inc.
• Becton, Dickinson and Company (BD)
• Pfizer Inc.
• Ethicon Inc.
• B. Braun SE
• Teleflex Incorporated
• CryoLife, Inc.
• Integra LifeSciences
• Advanced Medical Solutions Group plc
• GELITA AG

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References